15422-23-8

Basic information

• Product Name: 1-(biphenyl-2-yloxy)propan-2-one
• CAS NO: 15422-23-8
• Molecular Formula: C₁₅H₁₄O₂
• Molecular Weight: 226.2705
• Mol File: 15422-23-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 336.8°C at 760 mmHg
• Flash Point: 144.1°C
• Density: 1.083g/cm³
• Vapor Pressure: 0.00011mmHg at 25°C
• Refractive Index: 1.552
• CAS DataBase Reference: 1-(biphenyl-2-yloxy)propan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(biphenyl-2-yloxy)propan-2-one(15422-23-8)
• EPA Substance Registry System: 1-(biphenyl-2-yloxy)propan-2-one(15422-23-8)

Safety Data

• Hazardous Substances Data: 15422-23-8(Hazardous Substances Data)

Usage

General Description

1-(biphenyl-2-yloxy)propan-2-one is a chemical compound with the molecular formula C15H14O2. It is a ketone derivative that consists of a propan-2-one (or acetone) molecule with a biphenyl-2-yloxy group attached to one of its carbon atoms. 1-(biphenyl-2-yloxy)propan-2-one is commonly used in organic synthesis as a building block for the production of various pharmaceuticals and agrochemicals. It also has potential applications in the development of new materials and dyes. Additionally, 1-(biphenyl-2-yloxy)propan-2-one exhibits some biological activity and is being studied for its potential pharmacological properties. Overall, this chemical has diverse industrial uses and may have important implications in the fields of medicine and materials science.

Upstream product

• 78-95-5 chloroacetone 
• 90-43-7 2-Phenylphenol 

Relevant articles and documents

Novel 5-HT7R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile

A novel series of arylsulfonamide derivatives of (aryloxy)propyl piperidines was designed to obtain potent 5-HT7R antagonists. Among the compounds evaluated herein, 3-chloro-N-{1-[3-(1,1-biphenyl-2-yloxy)2-hydroxypropyl]piperidin-4-yl}benzenesulfonamide (25) exhibited antagonistic properties at 5-HT7R and showed selectivity over selected serotoninergic and dopaminergic receptors, as well as over serotonin, noradrenaline and dopamine transporters. Compound 25 demonstrated significant antidepressant-like activity in the forced swim test (0.625–2.5?mg/kg, i.p.) and in the tail suspension test (1.25?mg/kg, i.p.), augmented the antidepressant effect of inactive doses of escitalopram (selective serotonin reuptake inhibitor) and bupropion (dopamine reuptake inhibitor) in the FST in mice, and similarly to SB-269970, exerted pro-cognitive properties in the novel object recognition task in cognitively unimpaired conditions in rats (0.3?mg/kg, i.p.). Such an extended pharmacological profile, especially the augmentation effect of the identified 5-HT7R antagonist on SSRI activity, seems promising regarding the complexity of affective disorders and potentially improved outcomes, including mnemonic performance.